Material Safety Data Sheet Duloxetine Hydrochloride sc-207599 Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Duloxetine Hydrochloride STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA SUPPLIER Company: Santa Cruz Biotechnology, Inc. Address: 2145 Delaware Ave Santa Cruz, CA 95060 Telephone: 800.457.3801 or 831.457.3800 Emergency Tel: Luis Yanez at 831.251.2170 PRODUCT USE ! Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant used in the treatment of major depression and other mood disorders. They are also sometimes used to treat anxiety disorders, obsessive-compulsive disorder, attention deficit hyperactivity disorder (ADHD) and chronic neuropathic pain. They act upon two neurotransmitters in the brain that are known to play an important part in mood, namely, serotonin and norepinephrine. This can be contrasted with the more widely-used selective serotonin reuptake inhibitors (SSRIs), which act only on serotonin. Activity on norepinephrine reuptake is thought necessary for an antidepressant to be effective on neuropathic pain, a property shared with the older tricyclic antidepressants but not with the SSRIs. SNRIs were developed more recently than SSRIs, and there are relatively few of them. Their efficacy as well as their tolerability appear to be somewhat better than the SSRIs', apparently owing to their compound effect. Duloxetine is indicated in major depressive disorder (MDD), generalised anxiety disorder (GAD), pain related to diabetic neuropathy and fibromyalgia and in some countries for stress urinary incontinence SYNONYMS C18-H19-N-O-S.HCl, C18-H19-N-O-S.HCl, (+)-(S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-, amine, (+)-(S)-N-methyl- 3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-, amine, "(S)-duloxetine hydrochloride", (S)-N-(methyl-gamma-(1-naphthaleneyloxy)-2- thiophenepropanamine, hydrochloride, (S)-N-(methyl-gamma-(1-naphthaleneyloxy)-2-thiophenepropanamine, hydrochloride, (+)-S-N-methyl- gamma-(1-naphthyloxy)-2-thiophenepropylamine, hydrochloride, (+)-S-N-methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine, hydrochloride, (+)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, hydrochloride, (+)-N-methyl-3-(1-naphthalenyloxy)-3-(2- thienyl)propanamine, hydrochloride, LY-248686, "(RS)-duloxetine CAS RN:16817-11-9", "(RS)-duloxetine CAS RN:16817-11-9", antidepressant, Cymbalta, Yentreve Section 2 - HAZARDS IDENTIFICATION CANADIAN WHMIS SYMBOLS FLAMMABILITY 1 HEALTH HAZARD 3 INSTABILITY 0 1 of 15
15
Embed
Duloxetine Hydrochloridesearch.cosmobio.co.jp/cosmo_search_p/search_gate2/docs/...Duloxetine is indicated in major depressive disorder (MDD), generalised anxiety disorder (GAD), pain
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
PRODUCT NAMEDuloxetine Hydrochloride
STATEMENT OF HAZARDOUS NATURE
CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200.
NFPA
SUPPLIERCompany: Santa Cruz Biotechnology, Inc.
Address:
2145 Delaware Ave
Santa Cruz, CA 95060
Telephone: 800.457.3801 or 831.457.3800
Emergency Tel: Luis Yanez at 831.251.2170
PRODUCT USE! Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant used in the treatment of major depression and other
mood disorders. They are also sometimes used to treat anxiety disorders, obsessive-compulsive disorder, attention deficit hyperactivity
disorder (ADHD) and chronic neuropathic pain. They act upon two neurotransmitters in the brain that are known to play an important part in
mood, namely, serotonin and norepinephrine. This can be contrasted with the more widely-used selective serotonin reuptake inhibitors
(SSRIs), which act only on serotonin. Activity on norepinephrine reuptake is thought necessary for an antidepressant to be effective on
neuropathic pain, a property shared with the older tricyclic antidepressants but not with the SSRIs. SNRIs were developed more recently than
SSRIs, and there are relatively few of them. Their efficacy as well as their tolerability appear to be somewhat better than the SSRIs',
apparently owing to their compound effect. Duloxetine is indicated in major depressive disorder (MDD), generalised anxiety disorder (GAD),
pain related to diabetic neuropathy and fibromyalgia and in some countries for stress urinary incontinence
thienyl)propanamine, hydrochloride, LY-248686, "(RS)-duloxetine CAS RN:16817-11-9", "(RS)-duloxetine CAS RN:16817-11-9",
antidepressant, Cymbalta, Yentreve
Section 2 - HAZARDS IDENTIFICATION
CANADIAN WHMIS SYMBOLS
FLAMMABILITY1HEALTH HAZARD3 INSTABILITY0
1 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
EMERGENCY OVERVIEW
RISKHarmful if swallowed.
Risk of serious damage to eyes.
Possible risk of harm to the unborn child.
Very toxic to aquatic organisms.
POTENTIAL HEALTH EFFECTS
ACUTE HEALTH EFFECTS
SWALLOWED! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may
produce serious damage to the health of the individual.
! As with the SSRIs, abrupt discontinuation of SNRI-medication usually leads to a discontinuation syndrome which could include states of
anxiety and further symptoms. Because one of the actions of the SNRIs is to block the reuptake of serotonin as the SSRIs do, it has many of
the same side effects. The most common include nausea, drowsiness, headache, changes in appetite, vivid dreams, and sexual side effects.
There are two common sexual side effects: diminished interest in sex (libido) and difficulty reaching climax (orgasm). These drugs typically
do not cause problems with erection, but the sexual side effects are the most common reason people stop taking this type of antidepressant
even if it is working well.
One rarely mentioned side effect which is hardly mentioned in the literature is a decreased ability to perform normal physical activities.
Examples of this include exhaustion following house chores or inability to complete even an easy work-out routine without napping
afterwards.
Activity at the norepinephrine transporter can sometimes cause anxiety, activation, and elevated blood pressure, leading to the
recommendation that everyone who takes these medications should have their blood pressure monitored. SNRIs should be taken with
caution when using St John's wort, and should never be taken with MAOI antidepressants.
! Serotonin syndrome (serious changes to how the brain, muscles and digestive system works due to high levels of serotonin in the body)
may occur in therapy. Signs and symptoms of serotonin syndrome include
restlessness
fast heart beat
fast changes in blood pressure
diarrhoea and vomiting
nausea
hallucinations
increased body temperature
coma
loss of coordination
overactive reflexes
General side effects of serotonin reuptake inhibitors (SSRIs) are mostly present during the first 1-4 weeks while the body adapts to the drug
(with the exception of sexual side effects, which tend to occur later in treatment). In fact, it often takes 6-8 weeks for the drug to begin
reaching its full potential (the slow onset is considered a downside to treatment with SSRIs). Almost all SSRIs are known to cause one or
more of these symptoms:
anhedonia (inability to experience pleasure from normally pleasurable life events such as eating, exercise, and social or sexual
interaction.)
nausea
drowsiness or somnolence
headache
clenching of teeth
extremely vivid and strange dreams
dizziness
changes in appetite
weight loss/gain (measured by a change in bodyweight of 7 pounds)
may result in a double risk of bone fractures and injuries
2 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
changes in sexual behaviour
increased feelings of depression and anxiety (which may sometimes provoke panic attacks)
tremors
autonomic dysfunction including orthostatic tension, increased or reduced sweating
akathisia (a syndrome characterised by unpleasant sensations of "inner" restlessness that manifests itself with an inability to sit still or
remain motionless)
liver or renal impairment
thoughts of suicide
Photosensitivity (increased risk of sunburn) (Use protective clothing, such as long sleeves and hats, and sunscreen to decrease the risk
of sunburn.)
Common gastrointestinal side effects include nausea, vomiting, and diarrhoea, which are brought about by the actions of serotonin on the
gastrointestinal tract.
Most side effects usually disappear after the adaptation phase, when the antidepressive effects begin to show. However, despite being called
general, the side effects and their durations are highly individual and drug-specific. Usually the treatment is begun with a small dose to see
how the patient's body reacts to the drug, after that either the dose can be adjusted
Mania or hypomania is a possible side-effect. Users with some type of bipolar disorder are at a much higher risk, however SSRI-induced
mania in patients previously diagnosed with unipolar depression can trigger a bipolar diagnosis.
Sexual dysfunction: SSRIs can cause various types of sexual such as anorgasmia, erectile dysfunction, and diminished libido. Initial studies
found that such side effects occur in less than 10% of patients, but since these studies relied on unprompted reporting, the frequency was
probably underestimated. In more recent studies, doctors have specifically asked about sexual difficulties, and found that they are present in
between 17% and 41% of patients. This dysfunction occasionally disappears spontaneously without stopping the SSRI, and in most cases
resolves after discontinuation. In some cases, however, it does not; this is known as Post SSRI Sexual Dysfunction (PSSD).
It is believed that sexual dysfunction is caused by an SSRI induced reduction in dopamine. Stimulation of postsynaptic 5-HT2 and 5-HT3
receptors decreases dopamine release from the Substantia nigra.
Cardiovascular side effects are very rare with SSRI use, with a reported incidence of less than 0.0003 percent. SSRIs inhibit cardiac and
vascular sodium, calcium and potassium channels and prolong QT intervals. However, a number of large studies of patients without known
pre-existing heart disease have reported no EKG changes related to SSRI use. In overdose, fluoxetine has been reported to cause sinus
tachycardia, myocardial infarction, junctional rhythms and trigeminy. Some authors have suggested electrocardiographic monitoring in
patients with severe pre-existing cardiovascular disease who are taking SSRI's.
Discontinuation syndrome: SSRIs are addictive as discontinuing their use is known to produce both somatic and psychological withdrawal
symptoms.
Suicidality and aggression: Similarly to other antidepressants, SSRIs can cause suicidality in children. A 2004 Food and Drug Administration
(FDA) analysis of clinical trials on children with major depressive disorder found statistically significant increases of the risks of "possible
suicidal ideation and suicidal behavior" by about 80%, and of agitation and hostility by about 130%. An additional analysis by the FDA also
indicated 1.5-fold increase of suicidality in the 18–24 age group. This resulted in a black box warning on SSRI and other antidepressant
medications regarding the increased risk of suicidality in patients younger than 24. In 2004, the Medicines and Healthcare products
Regulatory Agency (MHRA) in the United Kingdom judged fluoxetine (Prozac) to be the only antidepressant that offered a favorable
risk-benefit ratio in children with depression, though it was also associated with a slight increase in the risk of self-harm and suicidal ideation.
Only two SSRIs are licensed for use with children in the UK, sertraline (Zoloft) and fluvoxamine (Luvox), and only for the treatment of
obsessive-compulsive disorder. Fluoxetine, despite having a favorable risk-benefit ratio for use with depression in adolescents and children,
is not licensed for this use.
Other studies on SSRIs and suicide among adolescents are equivocal; rates of suicide attempts in high-risk populations appear to be
unaffected by SSRI prescriptions in adults. There is also evidence that higher rates of SSRI prescriptions are associated with lower rates of
suicide in children, though since the evidence is correlational, the true nature of the relationship is unclear. The introduction of a warning
regarding the association between SSRIs and suicide led to a decrease in prescriptions for the medications in 2003 and 2004, and these
decreases in prescriptions were associated with an increase in actual number of teenage suicide.
Interaction with carbohydrate metabolism: Serotonin is also involved in regulation of carbohydrate metabolism. Few analyses of the role of
SSRIs in treating depression cover the effects on carbohydrate metabolism from intervening in serotonin handling by the body.
Pregnancy: When taken by pregnant women, selective serotonin reuptake inhibitors (SSRIs) cross the placenta and have the potential to
affect newborns. Sertraline and paroxetine have been associated with congenital malformations. Some evidence suggests that SSRIs are
associated with neonatal complications such as neonatal abstinence syndrome (NAS) and persistent pulmonary hypertension (PPHN).
Neonatal abstinence syndrome is a withdrawal syndrome in newborn babies which has been documented in SSRI treatment.
Persistent pulmonary hypertension (PPHN) is a serious and life-threatening, but rare, lung condition that occurs soon after birth of the
newborn. Newborn babies with PPHN have high pressure in their lung blood vessels and are not able to get enough oxygen into their
bloodstream. About 1 to 2 babies per 1000 babies born in the U.S. develop PPHN shortly after birth, and often they need intensive medical
care. One study has found that PPHN is six times more common in babies whose mothers take an SSRI antidepressant after the 20th week
of the pregnancy compared to babies whose mothers do not take an antidepressant.[.
EYE! If applied to the eyes, this material causes severe eye damage.
SKIN! There is some evidence to suggest that this material can cause inflammation of the skin on contact in some persons.
3 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
! This material is a photosensitizer. Certain individuals working with this substance may show allergic reaction of the skin under sunlight. This
results in sensitivity to sunburn (may be severe) unless protective covering and 15+PF sunscreen are used. Responses may vary from
sunburn-like effects to swelling and blistering lesions.
! Open cuts, abraded or irritated skin should not be exposed to this material.
! Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine
the skin prior to the use of the material and ensure that any external damage is suitably protected.
INHALED! The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless inhalation of dusts, or fume,
especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.
! Inhalation of dusts, generated by the material during the course of normal handling, may be damaging to the health of the individual.
! Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further
disability if excessive concentrations of particulate are inhaled.
CHRONIC HEALTH EFFECTS! Long-term exposure to the product is not thought to produce chronic effects adverse to the health (as classified using animal models);
nevertheless exposure by all routes should be minimized as a matter of course.
Results in experiments suggest that this material may cause disorders in the development of the embryo or fetus, even when no signs of
poisoning show in the mother.
Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5
micron penetrating and remaining in the lung. Prime symptom is breathlessness; lung shadows show on X-ray.
Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS
HAZARD RATINGS
Min Max
Flammability: 1
Toxicity: 2
Body Contact: 3
Reactivity: 1
Chronic: 2
Min/Nil=0
Low=1
Moderate=2
High=3
Extreme=4
NAME CAS RN %
duloxetine hydrochloride 136434-34-9 >98
Section 4 - FIRST AID MEASURES
SWALLOWED!
IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.
Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed
otherwise:
For advice, contact a Poisons Information Center or a doctor.
Urgent hospital treatment is likely to be needed.
If conscious, give water to drink.
INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down
position, if possible) to maintain open airway and prevent aspiration.
NOTE: Wear a protective glove when inducing vomiting by mechanical means.
In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as
indicated by the patient's condition.
If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the
MSDS should be provided. Further action will be the responsibility of the medical specialist.
If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the MSDS.
EYE
4 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
! If this product comes in contact with the eyes:
Immediately hold eyelids apart and flush the eye continuously with running water.
Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper
and lower lids.
Continue flushing until advised to stop by the Poisons Information Center or a doctor, or for at least 15 minutes.
Transport to hospital or doctor without delay.
Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
SKIN! If skin contact occurs:
Immediately remove all contaminated clothing, including footwear
Flush skin and hair with running water (and soap if available).
Seek medical attention in event of irritation.
INHALED!
If fumes or combustion products are inhaled remove from contaminated area.
Lay patient down. Keep warm and rested.
Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.
Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained.
Perform CPR if necessary.
Transport to hospital, or doctor.
NOTES TO PHYSICIAN! Treat symptomatically.
For selective serotonin reuptake inhibitors (SSRIs):
Serotonin toxicity is more pronounced following supra-therapeutic doses and overdoses, and they merge in a continuum with the toxic effects
of overdose. The serotonergic toxicity of SSRIs increases with dose, but even in over-dose it is insufficient to cause fatalities from serotonin
syndrome in healthy adults. The syndrome occurs in approximately 14 to 16 percent of persons who overdose on SSRIs.
It is usually only when drugs with different mechanisms of action are mixed together that elevations of central nervous system serotonin
reach potentially fatal levels.
The symptoms are often described as a clinical triad of abnormalities:
oxides (SOx), other pyrolysis products typical of burning organic material.
May emit poisonous fumes.
6 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
FIRE INCOMPATIBILITY! Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids,chlorine bleaches, pool chlorine etc. as ignition may result.
PERSONAL PROTECTIONGlasses:
Gloves:
Respirator:
Particulate
Section 6 - ACCIDENTAL RELEASE MEASURES
MINOR SPILLS
!
Clean up waste regularly and abnormal spills immediately.
Avoid breathing dust and contact with skin and eyes.
Wear protective clothing, gloves, safety glasses and dust respirator.
Use dry clean up procedures and avoid generating dust.
Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof
machines designed to be grounded during storage and use).
Dampen with water to prevent dusting before sweeping.
Place in suitable containers for disposal.
MAJOR SPILLS
!
Clear area of personnel and move upwind.
Alert Emergency Responders and tell them location and nature of hazard.
Wear full body protective clothing with breathing apparatus.
Prevent, by any means available, spillage from entering drains or water course.
Stop leak if safe to do so.
Contain spill with sand, earth or vermiculite.
Collect recoverable product into labeled containers for recycling.
Neutralize/decontaminate residue.
Collect solid residues and seal in labeled drums for disposal.
Wash area and prevent runoff into drains.
After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
If contamination of drains or waterways occurs, advise emergency services.
PROTECTIVE ACTIONS FOR SPILL
From IERG (Canada/Australia)
Isolation Distance 25 meters
Downwind Protection Distance 250 meters
FOOTNOTES
1 PROTECTIVE ACTION ZONE is defined as the area in which people are at risk of harmful exposure. This zone assumes that random changes in wind direction confines the
vapour plume to an area within 30 degrees on either side of the predominant wind direction, resulting in a crosswind protective action distance equal to the downwind protective
action distance.
7 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
2 PROTECTIVE ACTIONS should be initiated to the extent possible, beginning with those closest to the spill and working away from the site in the downwind direction. Within
the protective action zone a level of vapour concentration may exist resulting in nearly all unprotected persons becoming incapacitated and unable to take protective action
and/or incurring serious or irreversible health effects.
3 INITIAL ISOLATION ZONE is determined as an area, including upwind of the incident, within which a high probability of localised wind reversal may expose nearly all persons
without appropriate protection to life-threatening concentrations of the material.
4 SMALL SPILLS involve a leaking package of 200 litres (55 US gallons) or less, such as a drum (jerrican or box with inner containers). Larger packages leaking less than 200
litres and compressed gas leaking from a small cylinder are also considered "small spills". LARGE SPILLS involve many small leaking packages or a leaking package of greater
than 200 litres, such as a cargo tank, portable tank or a "one-tonne" compressed gas cylinder.
5 Guide 151 is taken from the US DOT emergency response guide book.
6 IERG information is derived from CANUTEC - Transport Canada.
ACUTE EXPOSURE GUIDELINE LEVELS (AEGL) (in ppm)AEGL 1: The airborne concentration of a substance above which it is predicted
that the general population, including susceptible individuals, could
experience notable discomfort, irritation, or certain asymptomatic nonsensory
effects. However, the effects are not disabling and are transient and
reversible upon cessation of exposure.
AEGL 2: The airborne concentration of a substance above which it is predicted
that the general population, including susceptible individuals, could
experience irreversible or other serious, long-lasting adverse health effects
or an impaired ability to escape.
AEGL 3: The airborne concentration of a substance above which it is predicted
that the general population, including susceptible individuals, could
experience life-threatening health effects or death.
Section 7 - HANDLING AND STORAGE
PROCEDURE FOR HANDLING!
Avoid all personal contact, including inhalation.
Wear protective clothing when risk of exposure occurs.
Use in a well-ventilated area.
Prevent concentration in hollows and sumps.
DO NOT enter confined spaces until atmosphere has been checked.
DO NOT allow material to contact humans, exposed food or food utensils.
Avoid contact with incompatible materials.
When handling, DO NOT eat, drink or smoke.
Keep containers securely sealed when not in use.
Avoid physical damage to containers.
Always wash hands with soap and water after handling.
Work clothes should be laundered separately.
Launder contaminated clothing before re-use.
Use good occupational work practice.
Observe manufacturer's storing and handling recommendations.
Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence
of an appropriate ignition source.
Do NOT cut, drill, grind or weld such containers
In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety
authorisation or permit.
RECOMMENDED STORAGE METHODS! Glass container.
Lined metal can, Lined metal pail/drum
Plastic pail
Polyliner drum
Packing as recommended by manufacturer.
Check all containers are clearly labeled and free from leaks.
For low viscosity materials
8 of 15
Material Safety Data Sheet
Duloxetine Hydrochloride
sc-207599
Hazard Alert Code Key: EXTREME HIGH MODERATE LOW
Drums and jerricans must be of the non-removable head type.
Where a can is to be used as an inner package, the can must have a screwed enclosure.
For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.):
Removable head packaging;
Cans with friction closures and
low pressure tubes and cartridges may be used.
- Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact
with inner and outer packages * . - In addition, where inner packagings are glass and contain liquids of packing group I and II there must be
sufficient inert absorbent to absorb any spillage *. - * unless the outer packaging is a close fitting molded plastic box and the substances are
not incompatible with the plastic.
STORAGE REQUIREMENTS!
Store in original containers.
Keep containers securely sealed.
Store in a cool, dry, well-ventilated area.
Store away from incompatible materials and foodstuff containers.
Protect containers against physical damage and check regularly for leaks.
Observe manufacturer's storing and handling recommendations.
SAFE STORAGE WITH OTHER CLASSIFIED CHEMICALS
+ X + X X +
X: Must not be stored together
O: May be stored together with specific preventions
+: May be stored together
Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION
EXPOSURE CONTROLS
The following materials had no OELs on our records